Today, Alzheimer’s is a leading cause of death and over 560,000 Canadians are living with dementia as of 2016. This number is expected to rise to over 930,000 by 2031. These cases are weighing heavily on Canada’s health care system, and it will only increase as time goes on unless treatments are developed. Below is a brief history of the disease:
PMN: ProMIS Neurosciences is a development stage biotech company that discovers and develops game changing precision therapeutics for treatment of neurodegenerative diseases, specifically Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).
Learn more about investing – take a quick tour of 8020 Connect.Show me the quick tour tag_faces